Chargement en cours...
Construction of a human monoclonal antibody against bFGF for suppression of NSCLC
Compelling evidence implicates that overexpression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor 1 (FGFR1) in non-small cell lung cancer (NSCLC) drives tumor progression, can serve as prognostic biomarkers or therapeutic targets for NSCLC patients. But at present, we...
Enregistré dans:
| Publié dans: | J Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Ivyspring International Publisher
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5995934/ https://ncbi.nlm.nih.gov/pubmed/29896285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.24255 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|